Drug Description in Trials / DrugBank / KEGG DRUG /


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1(-)-Epicatechin1件: Epicatechin---2件: 86, 113
2(18F)FPGLU----1件: 86
3(Pyr1)apelin-13----1件: 86
4(S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid----1件: 86
5(S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM----1件: 86
6(S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM----1件: 86
7**Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter.1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
810-nitro-9(E)-octadec-9-enoic acid----1件: 86
911C-ACETATE2件: Acetate,
Acetic acid C-11
---4件: 6, 13, 86, 88
10120 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
11129Xe Hyperpolarized----1件: 86
1215 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
13150mg CXA-101件: CXA-10---1件: 86
14171----1件: 86
152-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide----1件: 86
162-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide1件: Acetamide---1件: 86
1720 mg sildenafil citrate by mouth1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
1820 mg/ml Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
1925% MTD sodium nitrite inhalation solution1件: Nitrite---1件: 86
20400 mg BIA 5-10581件: BIA---1件: 86
2145 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
224AU76----1件: 86
2366215-101----1件: 86
246R-BH41件: Sapropterin1件: D08505 --3件: 86, 124, 240
2575mg CXA-101件: CXA-10---1件: 86
2690 mg sodium nitrite inhalation solution1件: Nitrite---1件: 86
27: 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N-----1件: 86
28[11C]-GSK2256098 500 MBq1件: GSK2256098---1件: 86
29[18F] FES----1件: 86
30[18F]Fluoro-2-deoxy-2-D-glucose2件: D-glucose,
Dextrose, unspecified form
1件: D00009 --2件: 86, 88
31Access program - sildenafil citrate, Viagra, Revatio1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
32ACE-011----1件: 86
33ACE-011 / MK - 7962----1件: 86
34ACE-011 / MK-7962----1件: 86
35ACE-011/ MK-7962----1件: 86
36Acetamide1件: Acetamide---2件: 86, 154
37Acetaminophen1件: Acetaminophen1件: D00217 2件: PTGS1,
PTGS2 💬
23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬13件: 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337
38Acetate1件: Acetate---41件: 1, 2, 6, 10, 13, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 171, 206, 222, 224, 225, 227, 235, 251, 265, 288, 298, 299
39ACT - 064992----1件: 86
40ACT-050089----1件: 86
41ACT-050089 (Ro 61-0612)----1件: 86
42ACT-064992----5件: 51, 85, 86, 88, 210
43ACT-064992 / JNJ-67896062----1件: 86
44ACT-064992/ JNJ-67896062----1件: 86
45ACT-064992D----1件: 86
46ACT-178418----1件: 86
47ACT-293987----3件: 51, 86, 88
48ACT-293987 (NS-304)----1件: 86
49ACT-385781A----1件: 86
50ACT-385781A (Actelion Epoprostenol)1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
51ActRIIA-IgG1Fc----1件: 86
52Adcirca1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
53ADCIRCA 20 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
54Adcirca®1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
55Adempas1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬5件: 51, 86, 88, 225, 299
56Adempas (Riociguat, BAY63-2521)1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 88
57ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
58ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 51, 86
59ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 51, 86
60ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 51, 86
61ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 51, 86
62Adempas 0.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299
63Adempas 0.5 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
64Adempas 1 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
65Adempas 1.0 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299
66Adempas 1.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
67Adempas 1.5 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
68Adempas 2 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
69Adempas 2.0 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 299
70Adempas 2.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
71Adempas 2.5 mg Film Coated Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
72Adempas®1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬2件: 86, 88
73Adempas® 0.5 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
74Adempas® 1.0 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
75Adempas® 1.5 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
76Adempas® 2.0 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
77Adempas® 2.5 mg film-coated tablets1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
78Adempas¿ 0.5 mg compressa rivestita con film1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
79Adempas¿ 1.01件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
80Adempas¿ 1.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
81Adempas¿ 2.0 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
82Adempas¿ 2.5 mg1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
83Adipose derived mesenchymal stem cells----1件: 86
84AER-901 Solution for Nebulization----1件: 86
85Aerosolized iloprost1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
86AIR001----1件: 86
87AIR001 (sodium nitrite inhalation solution)1件: Nitrite---1件: 86
88AIR001 Inhalation Solution----1件: 86
89AIR001 Inhalation Solution (Expansion arm)----1件: 86
90AL----11件: 5, 6, 7, 13, 28, 51, 67, 86, 97, 114, 127
91Albuterol1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬7件: 12, 13, 86, 89, 113, 256, 299
92Albuterol.1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
93Allogeneic Human Cardiosphere-Derived Stem Cells----1件: 86
94Ambrisentan1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬7件: 51, 84, 85, 86, 88, 210, 211
95Ambrisentan - high dose1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
96Ambrisentan - low dose1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
97Ambrisentan 5 mg film-coated tablets1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
98Ambrisentan 5mg film-coated tablets [marketed product]1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
99Ambrisentan plus Spironolactone2件: Ambrisentan,
Spironolactone
2件: D00443 ,
D07077
2件: EDNRA,
NR3C2 💬
8件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
100Ambrisentan Tablet1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
101AMN107----2件: 34, 86
102Anakinra1件: Anakinra1件: D02934 2件: IL1R1,
IL1R2 💬
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬16件: 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 84, 86, 97, 106, 107, 299
103ANASTROZOLE1件: Anastrozole1件: D00960 1件: CYP19A1 💬3件: Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis 💬3件: 78, 86, 193
104Angiotensin1件: Angiotensin II2件: D00150 ,
D02014
2件: AGTR1,
AGTR2 💬
16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬7件: 17, 19, 46, 66, 86, 222, 224
105Apabetalone1件: Apabetalone1件: D11131 4件: BRD2,
BRD3,
BRD4,
BRDT 💬
-1件: 86
106APD811----1件: 86
107Apelin----1件: 86
108AR392830----1件: 86
109Aspirin1件: Acetylsalicylic acid1件: D00109 2件: PTGS1,
PTGS2 💬
23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬12件: 13, 22, 46, 49, 51, 58, 64, 86, 113, 158, 210, 231
110Assigned pulmonary hypertension medication----1件: 86
111Autologous EPCs transfected----1件: 86
112Autologous EPCs transfected with human eNOS----1件: 86
113AV-1011件: AV-101---2件: 6, 86
114Aviptadil1件: Aviptadil1件: D12127 --5件: 49, 51, 84, 85, 86
115AZD4831----1件: 86
116Background PAH Therapy----1件: 86
117Bardoxolone1件: Bardoxolone1件: D09584 --7件: 66, 67, 84, 85, 86, 218, 222
118Bardoxolone methyl2件: Bardoxolone,
Bardoxolone methyl
2件: D09584 ,
D09585
--7件: 66, 67, 84, 85, 86, 218, 222
119Bardoxolone methyl capsules2件: Bardoxolone,
Bardoxolone methyl
2件: D09584 ,
D09585
--4件: 66, 67, 86, 222
120BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester2件: Bardoxolone,
Bardoxolone methyl
2件: D09584 ,
D09585
--1件: 86
121BAY 63-2521----2件: 86, 88
122BAY 63-2521 0.06 %----1件: 86
123BAY 63-2521 0.3 %----1件: 86
124BAY 63-2521 coated tablets 0.5 mg----2件: 86, 88
125BAY 63-2521 coated tablets 1 mg----2件: 86, 88
126BAY 63-2521 coated tablets 1.5 mg----2件: 86, 88
127BAY 63-2521 coated tablets 2 mg----2件: 86, 88
128BAY 63-2521 coated tablets 2.5 mg----2件: 86, 88
129BAY 63-2521 IR tablets 0.5 mg----1件: 86
130BAY 63-2521 IR tablets 1 mg----1件: 86
131BAY 63-2521 IR tablets 1.0 mg----1件: 86
132BAY 63-2521 IR tablets 1.5 mg----1件: 86
133BAY 63-2521 IR tablets 2.0 mg----1件: 86
134BAY 63-2521 IR tablets 2.5 mg----1件: 86
135BAY 63-2521 Tablet----1件: 86
136BAY 63-2521 tablets 0.5 mg----2件: 86, 88
137BAY 63-2521 tablets 1 mg----2件: 86, 88
138BAY 63-2521 tablets 1.5 mg----2件: 86, 88
139BAY 63-2521 tablets 2 mg----2件: 86, 88
140BAY 63-2521 tablets 2.5 mg----2件: 86, 88
141Bay Q 6256----1件: 86
142BAY1237592----2件: 86, 88
143BAY63-2521----3件: 51, 86, 299
144Beetroot juice----2件: 67, 86
145Benzbromaron----1件: 86
146Benzbromaron AL----1件: 86
147BENZBROMARONE1件: Benzbromarone1件: D01056 1件: SLC22A12 💬-1件: 86
148Beraprost1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
149Beraprost Sodium1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
150Beraprost Sodium 314d Modified Release Tablets1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
151Beraprost Sodium Modified Release1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
152BH4----5件: 51, 86, 124, 240, 299
153BIA1件: BIA---2件: 6, 86
154BIA 5-10581件: BIA---1件: 86
155BIA-5-10581件: BIA---1件: 86
156Biological DMARDs----2件: 86, 107
157BISOPROLOL1件: Bisoprolol1件: D02342 1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 58, 67, 86, 113
158Bosentan1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
159Bosentan administration1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
160Bosentan and Sildenafil2件: Bosentan,
Sildenafil
3件: D01227 ,
D07538 ,
D08514
3件: EDNRA,
EDNRB,
PDE5A 💬
11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
161BOSENTAN MONOHIDRATO1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
162Bosentan monohydrat1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
163BOSENTAN MONOHYDRATE1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 51, 84, 86, 88
164Bosentan, Ambrisentan2件: Ambrisentan,
Bosentan
3件: D01227 ,
D07077 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
165BPS-314d-MR----1件: 86
166BPS-MR----1件: 86
167Bromure d'Ipratropium1件: Ipratropium---1件: 86
168BSF 208075----1件: 86
169BSF 208075 or LU 208075----1件: 86
170C07AB07----1件: 86
171C225----2件: 51, 86
172Capsaicin1件: Capsaicin1件: D00250 1件: TRPV1 💬2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬3件: 6, 86, 226
173Captopril1件: Captopril1件: D00251 1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬2件: 17, 86
174Carbon1件: Activated charcoal---6件: 6, 85, 86, 96, 97, 158
175Carbon monoxide2件: Activated charcoal,
Carbon monoxide
1件: D09706 --2件: 85, 86
176Carnitine1件: Levocarnitine1件: D02176 --9件: 5, 13, 58, 86, 96, 97, 265, 298, 316
177Carvedilol1件: Carvedilol1件: D00255 5件: ADRA1A,
ADRA1B,
ADRA1D,
ADRB1,
ADRB2 💬
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 57, 86, 113, 210
178Cetuximab1件: Cetuximab1件: D03455 1件: EGFR 💬48件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬2件: 51, 86
179Chlorhexidine1件: Chlorhexidine1件: D07668 --2件: 86, 299
180Cialis1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 51, 86
181Cialis 10 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 113
182Cialis 2.5 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 113
183CIALIS 20 mg comprimidos recubiertos con película1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
184Cialis 20 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 113
185Cialis 5 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 113
186Cicletanine1件: Cicletanine1件: D03487 --1件: 86
187Cicletanine hydrochloride1件: Cicletanine1件: D03487 --1件: 86
188Citrulline1件: Citrulline---2件: 86, 113
189CJNJ-68150420-ZZZ-G001 (ACT- 064992D)----1件: 86
190CJNJ-68150420-ZZZ-G001 (ACT-064992D)----1件: 86
191CJNJ-68150420-ZZZ-G001(ACT-064992D)----1件: 86
192Clopidogrel1件: Clopidogrel3件: D07729 ,
D10823 ,
D10824
1件: P2RY12 💬1件: Platelet activation 💬3件: 49, 51, 86
193Coenzyme Q-101件: Ubidecarenone1件: D01065 --1件: 86
194Coenzyme Q-10 in Normal Control subjects1件: Ubidecarenone1件: D01065 --1件: 86
195Coenzyme Q-10 in Pulmonary Hypertension subjects1件: Ubidecarenone1件: D01065 --1件: 86
196Combination Product:----1件: 86
197Combination Product: Implantable System for Remodulin (treprostinil)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
198Combination Product: Treprostinil via implanted pump1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
199Commercial Ventavis® (iloprost)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
200Conivaptan1件: Conivaptan1件: D07748 2件: AVPR1A,
AVPR2 💬
5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬1件: 86
201Conventional drug therapy(expectorant,bronchodilator)----1件: 86
202CosmoFer----3件: 86, 96, 97
203CS1 Administration----1件: 86
204Current marketed FLOLAN (epoprostenol sodium)1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
205CXA-101件: CXA-10---2件: 86, 222
206D-glucose1件: D-glucose1件: D00009 --3件: 49, 86, 88
207D.3.6.2 - dose massima specificare: giornaliera----1件: 86
208Dapagliflozin1件: Dapagliflozin1件: D08897 1件: SLC5A2 💬-7件: 19, 49, 66, 67, 86, 88, 222
209Dapagliflozin 10 MG [Farxiga]1件: Dapagliflozin1件: D08897 1件: SLC5A2 💬-2件: 86, 88
210DHEA1件: Prasterone1件: D08409 3件: AR,
ESR1,
ESR2 💬
12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬3件: 49, 86, 96
211DHEA tablet1件: Prasterone1件: D08409 3件: AR,
ESR1,
ESR2 💬
12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 86
212Dichloroacetate1件: Dichloroacetic acid---1件: 86
213Dichloroacetate Sodium2件: Dichloroacetic acid,
Sodium dichloroacetate
1件: D05857 3件: PDK2,
PDK3,
PDK4 💬
1件: Diabetic cardiomyopathy 💬1件: 86
214Diet----4件: 86, 97, 240, 299
215Dietanolamina de treprostinilo1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
216Diltiazem1件: Diltiazem1件: D07845 4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬
37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 51, 58, 86
217Diltiazem Hydrochloride1件: Diltiazem1件: D07845 4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬
37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
218DIMETHYL FUMARATE1件: Dimethyl fumarate1件: D03846 1件: KEAP1 💬6件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬4件: 13, 51, 86, 296
219Dimethyl Fumarate (DMF)1件: Dimethyl fumarate1件: D03846 1件: KEAP1 💬6件: Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬3件: 13, 51, 86
220Diphenhydramine1件: Diphenhydramine1件: D00300 1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬8件: 11, 13, 49, 51, 70, 86, 222, 256
221Dobutamine1件: Dobutamine1件: D03879 1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 57, 58, 86, 215
222Dobutamine test1件: Dobutamine1件: D03879 1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
223Duo-Therapy with Sildenafil + Bosentan2件: Bosentan,
Sildenafil
3件: D01227 ,
D07538 ,
D08514
3件: EDNRA,
EDNRB,
PDE5A 💬
11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
224EFI/ACT-385781A----1件: 86
225Elafin1件: Elafin---1件: 86
226Endothelin receptor antagonist therapy----1件: 86
227Endothelin Receptor Antagonists----1件: 86
228Endothelin-3----1件: 86
229ENOS transfected EPCs will be delivered via a PA line----1件: 86
230Epicatechin1件: Epicatechin---2件: 86, 113
231EPOPROSTENOL1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
232Epoprostenol for injection1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
233EPOPROSTENOL SODICO1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
234EPOPROSTENOL SODIUM1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
235Epoprostenol-Actelion1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
236Epoprostenolo per iniezione----1件: 86
237Equal----4件: 6, 13, 67, 86
238ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)4件: Bosentan,
Macitentan,
Sildenafil,
Tadalafil
5件: D01227 ,
D02008 ,
D07538 ,
D08514 ,
D10135
3件: EDNRA,
EDNRB,
PDE5A 💬
11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
239ERA as specific PAH treatment----1件: 86
240Erbitux1件: Cetuximab1件: D03455 1件: EGFR 💬48件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬2件: 51, 86
241Esomeprazole1件: Esomeprazole1件: D07917 2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬8件: 13, 46, 86, 98, 107, 113, 298, 299
242ESR-specific PET scan----1件: 86
243Esuberaprost----1件: 86
244Eutonic Treprostinil Solution1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
245Famotidine1件: Famotidine1件: D00318 1件: HRH2 💬3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬5件: 6, 46, 86, 98, 107
246Famotidine 20 MG1件: Famotidine1件: D00318 1件: HRH2 💬3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬1件: 86
247FDC macitentan/tadalafil2件: Macitentan,
Tadalafil
2件: D02008 ,
D10135
3件: EDNRA,
EDNRB,
PDE5A 💬
11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
248Ferinject----2件: 86, 299
249Ferinject or CosmoFer----1件: 86
250FERRIC CARBOXYMALTOSE1件: Ferric carboxymaltose1件: D08920 --4件: 86, 96, 97, 299
251Ferricarboxymaltose----1件: 86
252FK506 level 2-3 ng/ml----1件: 86
253FK506 level 3-5 ng/ml----1件: 86
254FK506 level < 2 ng/ml----1件: 86
255Flolan1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
256FLOLAN injection with currently marketed diluent1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
257FLOLAN injection with reformulated diluent1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
258FLOLAN TM and Glycine Diluent2件: Epoprostenol,
Glycine
2件: D00011 ,
D00106
1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
259Flolan®1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
260FLOLAN™ and Glycine Diluent2件: Epoprostenol,
Glycine
2件: D00011 ,
D00106
1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
261FLUOXETINE1件: Fluoxetine1件: D00326 1件: SLC6A4 💬2件: Serotonergic synapse, Synaptic vesicle cycle 💬4件: 13, 17, 78, 86
262Forxiga1件: Dapagliflozin1件: D08897 1件: SLC5A2 💬-2件: 86, 88
263Forxiga (dapagliflozin)1件: Dapagliflozin1件: D08897 1件: SLC5A2 💬-2件: 86, 88
264Fulvestrant1件: Fulvestrant1件: D01161 2件: ESR1,
ESR2 💬
10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 86
265Furosemide1件: Furosemide1件: D00331 1件: SLC12A2 💬3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬2件: 6, 86
266G04BE03----1件: 86
267G04BE03- Sildenafil - sildenafil (citrato)1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
268G04BE08----1件: 86
269GB002----1件: 86
270GB002 (seralutinib)----1件: 86
271GB002 Capsules----1件: 86
272GLIVEC1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬2件: 51, 86
273GLIVEC 100 mg comprimidos recubiertos con película1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬2件: 34, 86
274Glivec 100 mg Filmtabletten1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬2件: 51, 86
275Glivec 100 mg Hartkapsel1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
276Glivec®1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
277Glivec® 100 mg Filmtabletten1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
278Glucose1件: Dextrose, unspecified form---12件: 2, 6, 13, 49, 50, 66, 86, 88, 96, 97, 257, 299
279GLYCINE1件: Glycine1件: D00011 --5件: 35, 60, 86, 226, 299
280GMA301 Injection----1件: 86
281Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318
282GS-4997 18 mg----1件: 86
283GS-4997 2 mg----1件: 86
284GS-4997 6 mg----1件: 86
285GSK1325760----2件: 86, 88
286GSK1325760A----1件: 86
287GSK22560981件: GSK2256098---1件: 86
288GSK2586881----1件: 86
289HGP1206----1件: 86
290Hydroxyurea1件: Hydroxyurea1件: D00341 1件: RRM2 💬7件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway 💬8件: 3, 13, 19, 20, 65, 85, 86, 284
291Hyperpolarized 129Xe----1件: 86
292Hyperpolarized Xe129----4件: 51, 85, 86, 299
293HypotonicTreprostinil Solution----1件: 86
294I.v. selexipag1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
295Ilomedin 20----1件: 86
296Ilomedin 20 [20 µg / ml]----1件: 86
297Iloprost1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬4件: 51, 84, 85, 86
298Iloprost (5 µg)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
299Iloprost (Ventavis BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
300Iloprost (Ventavis inhaled, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
301Iloprost (Ventavis, BAYQ 6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
302Iloprost (Ventavis, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
303Iloprost (Ventavis®)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
304Iloprost Inhalation Solution (Ventavis)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 85, 86
305Iloprost PD-151件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
306Iloprost PD-61件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
307Iloprost,(Ventavis, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
308Imatinib1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
309IMATINIB MESILATE1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬3件: 13, 86, 88
310Imatinib Mesylate1件: Imatinib1件: D08066 3件: ABL1,
KIT,
PDGFRA 💬
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬5件: 13, 28, 34, 51, 86
311Inhaled dry powder treprostinil (LIQ861)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
312Inhaled Iloprost (5 µg)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
313Inhaled iloprost (Ventavis, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
314Inhaled Nitric Oxide1件: Nitric Oxide1件: D00074 --2件: 85, 86
315Inhaled nitric oxide & INOpulse delivery1件: Nitric Oxide1件: D00074 --1件: 86
316Inhaled nitric oxide 75 mcg/kg IBW/hr1件: Nitric Oxide1件: D00074 --2件: 85, 86
317Inhaled NO with pulsed delivery----1件: 86
318Inhaled prostacyclin1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
319Inhaled Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬3件: 84, 85, 86
320INO----2件: 85, 86
321Intestinal microbiota transplant (IMT)----1件: 86
322Intravenous administration of ferric carboxymaltose1件: Ferric carboxymaltose1件: D08920 --1件: 86
323Intravenous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
324Ipratropium1件: Ipratropium---2件: 6, 86
325Iron supplement----1件: 86
326JNJ-67896049----1件: 86
327JNJ-67896049 (ACT-293987)----1件: 86
328JNJ-67896062 / ACT-064992----2件: 86, 88
329JNJ-67896062/ ACT-064992----2件: 86, 88
330JNJ-67896062/ACT-064922----1件: 86
331JTT-251----1件: 86
332KAR5585 Capsules----1件: 86
333L-Carnitine1件: Levocarnitine1件: D02176 --7件: 13, 86, 96, 97, 265, 298, 316
334L-Citrulline Malate1件: Citrulline---1件: 86
335L606 (Liposomal Treprostinil) Inhalation Solution 51ug1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
336Levitra1件: Vardenafil1件: D08668 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 13, 86
337Lidocaine1件: Lidocaine2件: D00358 ,
D08127
5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬12件: 6, 13, 22, 34, 46, 51, 70, 86, 107, 168, 226, 256
338LIQ861 100 µg----1件: 86
339LIQ861 106 µg----1件: 86
340LIQ861 25 µg----1件: 86
341LIQ861 26.5 µg----1件: 86
342LIQ861 50 µg----1件: 86
343LIQ861 53 µg----1件: 86
344LIQ861 75 µg----1件: 86
345LIQ861 79.5 µg----1件: 86
346LIQ861 Inhaled Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
347LISURIDE1件: Lisuride1件: D08132 3件: DRD2,
DRD3,
DRD4 💬
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬2件: 6, 86
348Lloprost(Ventavis,BAYQ6252, 10 µg/mL)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
349Lloprost(Ventavis,BAYQ6252, 20 µg/mL)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
350LTP001----2件: 85, 86
351LY450190----1件: 86
352Macitentan1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬5件: 51, 85, 86, 88, 210
353Macitentan (ACT-064992)1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
354Macitentan 10 mg1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 51, 86, 88
355Macitentan 10 mg tablet, once daily.1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
356Macitentan 37.5 mg1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
357Macitentan 75 mg1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
358MACITENTAN COMPRESSE1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 86, 88
359Macitentan Group1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
360MACITENTAN TABLETS1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 86, 88
361MD-711----1件: 86
362Medical air2件: Medical air,
Oxygen
1件: D00003 --3件: 85, 86, 193
363Metformin1件: Metformin1件: D04966 2件: PRKAA1,
PRKAA2 💬
20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬25件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301
364Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo----1件: 86
365Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb----2件: 86, 88
366Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth----2件: 86, 88
367Methylprednisolone1件: Methylprednisolone1件: D00407 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬46件: 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296
368MK-4836----2件: 86, 88
369MK-5475----1件: 86
370MK-7962----1件: 86
371MK-8892----1件: 86
372MN-08 24 mg/day----1件: 86
373MN-08 60 mg/day----1件: 86
374Mono-Therapy with Sildenafil1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
375Morphine1件: Morphine1件: D08233 1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬5件: 36, 46, 70, 85, 86
376MORPHINE SULFATE2件: Morphine,
Sulfate ion
1件: D08233 1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬3件: 46, 85, 86
377Moxifloxacin1件: Moxifloxacin1件: D08237 --9件: 2, 6, 46, 49, 85, 86, 113, 240, 299
378Moxifloxacin 400 mg1件: Moxifloxacin1件: D08237 --1件: 86
379MultiHance1件: Gadobenic acid1件: D08018 --2件: 86, 88
380Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬1件: 86
381Nebulized combination ipratropium bromide with salbutamol2件: Ipratropium,
Salbutamol
1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
382Nebulized ipratropium bromide1件: Ipratropium---1件: 86
383New thermo stable formulation of epoprostenol sodium1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
384Nicardipine1件: Nicardipine1件: D08270 4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬
37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 70, 86
385Nilotinib1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬5件: 6, 8, 34, 51, 86
386Nilotinib 50 mg1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
387NITRIC OXIDE1件: Nitric Oxide1件: D00074 --7件: 85, 86, 88, 210, 251, 294, 299
388Nitric Oxide for inhalation1件: Nitric Oxide1件: D00074 --2件: 86, 299
389Nitric Oxide generated by the GeNO nitrosyl delivery system1件: Nitric Oxide1件: D00074 --1件: 86
390Nitric Oxide plus Oxygen2件: Nitric Oxide,
Oxygen
2件: D00003 ,
D00074
--1件: 86
391Nitrite1件: Nitrite---2件: 58, 86
392Nitrosyl1件: Nitric Oxide1件: D00074 --1件: 86
393NO----9件: 6, 46, 58, 62, 86, 97, 222, 299, 321
394Non-Biologic DMARDs----3件: 46, 86, 107
395NS-304----3件: 70, 86, 88
396Null----16件: 6, 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271
397NX1011----1件: 86
398Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi4件: Epoprostenol,
Iloprost,
Macitentan,
Selexipag
4件: D00106 ,
D02721 ,
D09994 ,
D10135
3件: EDNRA,
EDNRB,
PTGIR 💬
10件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
399Olaparib1件: Olaparib1件: D09730 2件: PARP1,
PARP2 💬
5件: Apoptosis, Base excision repair, Diabetic cardiomyopathy, NF-kappa B signaling pathway, Necroptosis 💬2件: 86, 285
400Opsumit1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 86, 88, 210
401Opsumit (macitentan)1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
402Opsumit®1件: Macitentan1件: D10135 2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 86, 88, 210
403Oral anticoagulant treatment----1件: 86
404Oral ERA----1件: 86
405Oral PDE5 inhibitors----1件: 86
406Oral selexipag (Uptravi)1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
407Oral sildenafil1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
408Oral treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 51, 86
409Oral treprostinil (UT-15C) Sustained Release Tablets1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
410Ossido Nitrico----1件: 86
411Oxygen1件: Oxygen1件: D00003 --13件: 6, 49, 70, 85, 86, 88, 90, 96, 168, 193, 271, 299, 330
412Oxygen supplementation1件: Oxygen1件: D00003 --1件: 86
413Oxygen, liquid1件: Oxygen1件: D00003 --2件: 86, 88
414PAH----3件: 49, 53, 86
415PAH medication----1件: 86
416PAH Therapies----1件: 86
417Parenteral Remodulin (treprostinil) injection1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
418Parenteral Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
419PB1046----1件: 86
420PB1046 Subcutaneous Injection----1件: 86
421PB1046, VIP-ELP1-120, Vasomera----1件: 86
422PDE5 inhibitor----1件: 86
423Pemziviptadil (PB1046) Injection----1件: 86
424Pentoxifylline1件: Pentoxifylline1件: D00501 --12件: 26, 56, 84, 86, 93, 96, 97, 113, 220, 222, 296, 298
425PF-004897911件: PF-00489791---1件: 86
426Pioglitazone1件: Pioglitazone1件: D08378 1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
427Placebo----28件: 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276
428PLX-PAD1件: Placental Mesenchymal Stem Cells---1件: 86
429Prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬45件: 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331
430Prostacyclin1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
431Prostacyclin Receptor Agonist1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
432Puri-Nethol----3件: 86, 96, 97
433Q4W GMA301 IV injections (1000 mg)----1件: 86
434Q4W GMA301 IV injections (300 mg)----1件: 86
435Q4W GMA301 IV injections (600 mg)----1件: 86
436QCC374----1件: 86
437QCC374 0.015 mg----1件: 86
438QCC374 0.06 mg----1件: 86
439QTI571----1件: 86
440Qutenza----1件: 86
441Qutenza (8% capsaicin)1件: Capsaicin1件: D00250 1件: TRPV1 💬2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 86
442RALINEPAG1件: Ralinepag1件: D10725 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
443Ranolazine1件: Ranolazine1件: D05700 --6件: 2, 58, 86, 96, 113, 114
444Rapamycin1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬18件: 15, 34, 35, 46, 49, 51, 53, 60, 61, 67, 86, 89, 96, 157, 158, 193, 256, 279
445Rapid Dose Titration Group of Subcutaneous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
446Recombinant Human Angiotensin-Converting Enzyme 22件: Alunacedase alfa,
Angiotensin II
2件: D00150 ,
D02014
2件: AGTR1,
AGTR2 💬
16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
447Recombinant Human Angiotensin-converting enzyme 2 (ACE2), APN012件: Alunacedase alfa,
Angiotensin II
2件: D00150 ,
D02014
2件: AGTR1,
AGTR2 💬
16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
448Remodulin1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 86, 88
449Remodulin (treprostinil sodium)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
450Remodulin® (treprostinil) 1 mg/ml solution for infusion1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
451Remodulin® (treprostinil) 10 mg/ml solution for infusion1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
452Remodulin® (treprostinil) 2.5 mg/ml solution for infusion1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
453Remodulin® (treprostinil) 5 mg/ml solution for infusion1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
454Revatio1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬3件: 85, 86, 113
455Revatio 10 mg/ml powder for oral suspension1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
456Revatio 20 mg film coated tablets1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
457Revatio 20 mg film-coated tablets----1件: 86
458Revatio 20 mg Filmtabletten1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
459REVATIO 20 mg, comprimidos recubiertos con película1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
460Revatio inyectable1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
461Revatio oral1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
462Revatio POS1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
463Revatio Tablets1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
464Revatio ® 20 mg film-coated tablets1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
465Revatio®1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
466Riciguat Group----1件: 86
467Rifampin1件: Rifampicin1件: D00211 --5件: 6, 13, 84, 86, 299
468RIOCIGUAT1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬6件: 51, 84, 86, 88, 225, 299
469Riociguat (Adempas, BAY63-2521)1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬4件: 51, 86, 88, 299
470Riociguat (BAY63-2521)1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
471Riociguat granules 0.3% for oral application1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
472Riociguat Oral Product1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
473Riociguat Oral Tablet1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬3件: 51, 86, 88
474Riociguat Pill1件: Riociguat1件: D09572 3件: GUCY1A1,
GUCY1A2,
GUCY1B1 💬
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 86
475Ritonavir1件: Ritonavir1件: D00427 --3件: 2, 86, 265
476RITUXIMAB1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
477Ro 47-0203----4件: 51, 85, 86, 88
478Ro 47-0203 / ACT-050088----1件: 86
479Ro-47-0203----1件: 86
480Ro-47-0203/029----1件: 86
481Ro47-0203----1件: 86
482Ro47-0203 / ACT-050088----2件: 51, 86
483RoActemra1件: Tocilizumab1件: D02596 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬11件: 40, 41, 44, 46, 50, 51, 86, 107, 266, 271, 331
484Rodatristat ethyl----1件: 86
485Rodatristat ethyl 300 mg tablet BID----1件: 86
486Rodatristat ethyl 600 mg BID----1件: 86
487RT234 - vardenafil inhalation powder1件: Vardenafil1件: D08668 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
488RTA 402----3件: 67, 86, 218
489RVG 33865----1件: 86
490RVT-1201----1件: 86
491Salbutamol1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬8件: 3, 11, 49, 85, 86, 111, 256, 299
492Saline----10件: 6, 13, 17, 53, 67, 78, 86, 97, 168, 299
493Sapropterin1件: Sapropterin1件: D08505 --3件: 86, 124, 240
494Sapropterin dihydrochloride (6R-BH4)1件: Sapropterin1件: D08505 --1件: 86
495Saquinavir1件: Saquinavir1件: D00429 --2件: 86, 265
496Saquinavir and ritonavir2件: Ritonavir,
Saquinavir
2件: D00427 ,
D00429
--1件: 86
497SATRALIZUMAB1件: Satralizumab1件: D11079 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬3件: 11, 13, 86
498Satralizumab (Genetical Recombination)1件: Satralizumab1件: D11079 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 86
499Sauerstoff----2件: 86, 88
500SELEXIPAG1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬5件: 51, 70, 84, 86, 88
501Selexipag (Uptravi)1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
502Selexipag, ACT-293987 (NS-304)1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
503Selonsertib1件: Selonsertib1件: D10988 1件: MAP3K5 💬20件: Alcoholic liver disease, Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Huntington disease, Lipid and atherosclerosis, MAPK signaling pathway, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Protein processing in endoplasmic reticulum, Sphingolipid signaling pathway, Spinocerebellar ataxia, TNF signaling pathway, Thermogenesis, Tight junction 💬1件: 86
504Seralutinib----1件: 86
505Serine1件: Serine1件: D00016 --4件: 2, 6, 86, 96
506Sham O2 (medical air)2件: Medical air,
Oxygen
1件: D00003 --1件: 86
507SILDENAF----1件: 86
508Sildenafil1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬17件: 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
509Sildenafil (as citrate)1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
510Sildenafil (REVATIO)1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
511Sildenafil (Revatio) 20 mg TID1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
512Sildenafil 20mg1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 51, 86
513Sildenafil 20mg and Bosentan 62.5mg2件: Bosentan,
Sildenafil
3件: D01227 ,
D07538 ,
D08514
3件: EDNRA,
EDNRB,
PDE5A 💬
11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 51, 86
514Sildenafil citrate1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬4件: 51, 85, 86, 225
515Sildenafil citrate (UK-92,480)1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
516Sildenafil Filmtabletten1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
517Sildenafil singly or in association with Bosentan2件: Bosentan,
Sildenafil
3件: D01227 ,
D07538 ,
D08514
3件: EDNRA,
EDNRB,
PDE5A 💬
11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
518SILDENAFILO1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
519Simvastatin1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
520Simvastatin 40 mg1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 86
521Simvastatin 40 mg tablets1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 86
522Sirolimus1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬35件: 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 300, 331
523Sitaxentan1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
524Sitaxentan sodium1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
525Sitaxsentan1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
526Sitaxsentan alone1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
527Sitaxsentan and Sildenafil2件: Sildenafil,
Sitaxentan
2件: D07171 ,
D08514
2件: EDNRA,
PDE5A 💬
9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
528SITAXSENTAN SODIUM1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
529Slow Dose Titration Group of Subcutaneous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
530SODIUM NITRITE1件: Nitrite---1件: 86
531Sodium Nitrite Inhalation Solution1件: Nitrite---1件: 86
532Sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth2件: Dextrose, unspecified form,
Sildenafil
1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
533Sorafenib1件: Sorafenib1件: D08524 8件: BRAF,
FLT3,
FLT4,
KDR,
KIT,
PDGFRB,
RAF1,
RET 💬
89件: Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬2件: 34, 86
534SOTATERCEPT1件: Sotatercept1件: D09670 1件: ACVR2A 💬4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬2件: 86, 284
535Sotatercept - 45 mg/vial1件: Sotatercept1件: D09670 1件: ACVR2A 💬4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 86
536Sotatercept - 60 mg/vial1件: Sotatercept1件: D09670 1件: ACVR2A 💬4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 86
537Spironolactone1件: Spironolactone1件: D00443 1件: NR3C2 💬1件: Aldosterone-regulated sodium reabsorption 💬8件: 46, 58, 67, 86, 113, 210, 218, 225
538Spironolactone and conivaptan2件: Conivaptan,
Spironolactone
2件: D00443 ,
D07748
3件: AVPR1A,
AVPR2,
NR3C2 💬
6件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption 💬1件: 86
539Spironolactone captopril carvedilol3件: Captopril,
Carvedilol,
Spironolactone
3件: D00251 ,
D00255 ,
D00443
7件: ACE,
ADRA1A,
ADRA1B,
ADRA1D,
ADRB1,
ADRB2,
NR3C2 💬
19件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Chagas disease, Chemical carcinogenesis - receptor activation, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
540STI571----2件: 51, 86
541Subcutaneous and intravenous prostacyclin1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
542Subcutaneous Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
543Sugar pill----8件: 5, 6, 49, 67, 70, 86, 206, 210
544SULFASALAZINE1件: Sulfasalazine1件: D00448 --6件: 46, 86, 94, 107, 270, 271
545Sulfate1件: Sulfate ion---27件: 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 85, 86, 96, 111, 218, 222, 224, 226, 265, 296, 297, 299
546Tadalafil1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬7件: 6, 51, 75, 84, 86, 113, 210
547Tadalafil 20 mg film-coated tablets1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
548Tadalafil 40 mg1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
549Tadalafil and ambrisentan upfront combination therapy2件: Ambrisentan,
Tadalafil
2件: D02008 ,
D07077
2件: EDNRA,
PDE5A 💬
9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 51, 86
550Tadalafil oral suspension1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
551Tadalafil- Tablet or Oral suspension1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
552TADALAFILO1件: Tadalafil1件: D02008 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬1件: 86
553Tasigna1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬2件: 34, 86
554Tasigna®1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
555Tasigna® 150 mg1件: Nilotinib1件: D08953 4件: ABL1,
KIT,
PDGFRA,
PDGFRB 💬
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬1件: 86
556TBD----5件: 19, 86, 90, 276, 299
557Tegaderm----1件: 86
558Terguride1件: Terguride1件: D01348 2件: DRD2,
PRL 💬
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬2件: 51, 86
559Terguride 0,5mg tablet1件: Terguride1件: D01348 2件: DRD2,
PRL 💬
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 86
560Terguride 0.5 mg tablet1件: Terguride1件: D01348 2件: DRD2,
PRL 💬
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 86
561Tezosentan1件: Tezosentan---1件: 86
562The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:----1件: 86
563The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:----1件: 86
564Thelin1件: Sitaxentan1件: D07171 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
565Threonine1件: Threonine1件: D00041 --2件: 86, 97
566Tocilizumab1件: Tocilizumab1件: D02596 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
567TOLVAPTAN1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬4件: 67, 72, 86, 225
568TPN171H----1件: 86
569TPN171H single dose----1件: 86
570Traclear----1件: 86
571Tracleer1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬8件: 13, 51, 84, 85, 86, 88, 210, 211
572TRACLEER 62,5 mg comprimidos recubiertos con película1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
573TRACLEER 62,5MG 56CPR RIV.1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
574TRACLEER*125MG 56CPR RIV.1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 51, 86
575TRACLEER*56CPR RIV 125MG1件: Bosentan2件: D01227 ,
D07538
2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 51, 86, 88
576Tracleer®----1件: 86
577Transdihydrolisuride----2件: 51, 86
578TRE----1件: 86
579Treprosinil Diethanolamine----1件: 86
580Treprostin----1件: 86
581Treprostinil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬6件: 51, 84, 85, 86, 88, 210
582Treprostinil dietanolamina1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
583Treprostinil diethanolamine1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬2件: 51, 86
584Treprostinil Diolamine1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
585Treprostinil Inhalation Powder1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
586Treprostinil inhalations1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
587Treprostinil Injectable Product1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
588Treprostinil Palmitil1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
589TREPROSTINIL SODIUM1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬3件: 51, 86, 88
590Treprostinil Sodium Solution for Inhalation1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
591TREPROSTINIL SODIUM, UT-151件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
592Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 8401件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
593Treprostinilo1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
594Trimetazidine1件: Trimetazidine1件: D08642 --3件: 2, 58, 86
595Trisuva(r)----1件: 86
596TRK-100STP----1件: 86
597Tyrosine1件: Tyrosine1件: D00022 --3件: 6, 86, 111
598Tyvaso1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
599Tyvaso Inhalation Solution1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
600Ubenimex1件: Ubenimex1件: D00087 1件: ANPEP 💬4件: Glutathione metabolism, Hematopoietic cell lineage, Metabolic pathways, Renin-angiotensin system 💬1件: 86
601Udenafil1件: Udenafil1件: D10027 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 86, 210
602UK 092480----1件: 86
603UK-92,480----1件: 86
604UK-92,480-10----1件: 86
605ULARITIDE1件: Ularitide---1件: 86
606Uptravi1件: Selexipag1件: D09994 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬3件: 84, 86, 88
607Urodilatin----1件: 86
608UT-15C----1件: 86
609UT-15C (treprostinil diethanolamine)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
610UT-15C 0.25 mg----1件: 86
611UT-15C 1 mg----1件: 86
612UT-15C 5 mg----1件: 86
613UT-15C LP----1件: 86
614UT-15C SR----2件: 51, 86
615UT-15C SR (treprostinil diethanolamine)1件: Treprostinil1件: D06213 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
616UT-15C-SR----2件: 51, 86
617Vardenafil1件: Vardenafil1件: D08668 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬3件: 13, 86, 299
618Vasomera (PB1046) Injection----1件: 86
619Veletri1件: Epoprostenol1件: D00106 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
620Ventavis1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
621Ventavis (Iloprost, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
622Ventavis 101件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
623Ventavis(Iloprost)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
624VIAGRA1件: Sildenafil1件: D08514 1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬3件: 86, 96, 225
625VIP----3件: 49, 51, 86
626Volibris1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 51, 85, 86, 88
627VOLIBRIS 10 mg comprimidos recubiertos con película1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
628VOLIBRIS 5 mg comprimidos recubiertos con película1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
629VOLIBRIS® (ambrisentan)1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
630VOLIBRIS™ tablets1件: Ambrisentan1件: D07077 1件: EDNRA 💬7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
631Warfarin1件: Warfarin1件: D08682 2件: NQO1,
VKORC1 💬
7件: Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬11件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91
632ZAMICASTAT1件: Zamicastat---1件: 86